Project Grant R01AI192405
Award Date
5/21/25
Completion Date
4/30/30
Dollars Obligated
$684K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $479,249 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Washington University located in Missouri. The grant aims to study the molecular mechanisms regulating neutrophil proinflammatory activity in sepsis, which is a leading cause of death in intensive care units. Specifically, the research will investigate how neutrophil A20 signaling contributes to organ damage and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $392,634 to the University of Wisconsin System to develop a novel nanoimmunotherapeutic approach for combating multidrug-resistant bacterial infections. The key product being developed is a red blood cell membrane-coated, hemoglobin-encapsulating nanoparticle (RHNP) that functions to sensitize bacteria to host...
This $186,221 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop personalized sepsis therapies for pediatric patients. The key objectives are to: Enhance sepsis phenotyping by integrating high-frequency physiologic data with electronic health records to identify additional subtypes and predict disease progression. Retrospectively develop and externally validate...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $721,728 to the Regents of the University of Michigan to conduct research on the modulation of pediatric sepsis by virus persistence. The research aims to investigate how persistent viral infections, even in the absence of reactivation, can affect clinical outcomes and response to immunomodulatory therapies in...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,583,391.00 to The Regents of the University of California, San Francisco (UCSF) to conduct research on sepsis pathogenesis and treatment. The key objectives are to: Identify known and novel pathogens responsible for septic shock using metagenomic sequencing of host and microbe samples. Discover novel sepsis...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $490,093 to the University of Maryland, College Park to develop a rapid antibiotic susceptibility testing platform. The goal is to create a microfluidic-enabled technology that can isolate small numbers of bacteria directly from whole blood, identify bacterial pathogens, and evaluate their antibiotic response within 75...
This $444,506 Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a human-centered artificial intelligence (HCAI) system to enhance early prediction and decision-making for sepsis. The key products and services to be delivered include: Creation of a de-identified database with comprehensive electronic health record (EHR) data for patients at risk of sepsis,...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) is providing $2,378,837 to the University of Massachusetts to develop novel nanopore- and click-chemistry-based approaches for the rapid, culture-independent detection of sepsis-causing pathogens directly from blood samples. The goal is to enable the early administration of source-directed antibiotics by detecting proteomic biomarkers, such as...
This $784,217 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research to characterize how cellular death programs contribute to both protective and injurious inflammation during bacterial infections. The award recipient, the Research Foundation of the City University of New York (RFCUNY) - Lehman College, will utilize human cells, murine genetics, and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $750,815 to the University of Maryland, Baltimore to conduct research on developing novel therapeutic strategies to treat mucormycosis, a deadly invasive fungal infection. The research aims to examine the role of the host cell hypoxia-response pathway in the pathogenesis of mucormycosis, and to identify and evaluate...